Published in Clin Cancer Res on January 15, 2005
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol (2006) 30.90
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
A sequence-based identification of the genes detected by probesets on the Affymetrix U133 plus 2.0 array. Nucleic Acids Res (2005) 3.45
Criteria for the use of omics-based predictors in clinical trials. Nature (2013) 3.15
Using RNA sample titrations to assess microarray platform performance and normalization techniques. Nat Biotechnol (2006) 3.13
The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics (2008) 3.11
Making sense of cancer genomic data. Genes Dev (2011) 3.01
Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood (2008) 1.95
Sources of variation in Affymetrix microarray experiments. BMC Bioinformatics (2005) 1.94
Reproducibility of microarray data: a further analysis of microarray quality control (MAQC) data. BMC Bioinformatics (2007) 1.92
Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. BMC Med (2013) 1.84
Use of a mixed tissue RNA design for performance assessments on multiple microarray formats. Nucleic Acids Res (2005) 1.70
Analysis of gene expression using gene sets discriminates cancer patients with and without late radiation toxicity. PLoS Med (2006) 1.55
Interlaboratory performance of a microarray-based gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers. J Mol Diagn (2007) 1.44
Cross platform microarray analysis for robust identification of differentially expressed genes. BMC Bioinformatics (2007) 1.39
Can subtle changes in gene expression be consistently detected with different microarray platforms? BMC Genomics (2008) 1.36
Identification of DOK genes as lung tumor suppressors. Nat Genet (2010) 1.32
18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis. J Nucl Med (2010) 1.30
A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys (2009) 1.24
The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol (2006) 1.21
In vitro transcription amplification and labeling methods contribute to the variability of gene expression profiling with DNA microarrays. J Mol Diagn (2006) 1.14
Review of the literature examining the correlation among DNA microarray technologies. Environ Mol Mutagen (2007) 1.14
A longitudinal study of gene expression in healthy individuals. BMC Med Genomics (2009) 1.11
Comparison of the latest commercial short and long oligonucleotide microarray technologies. BMC Genomics (2006) 1.11
Gene expression profiling of non-small cell lung cancer. Lung Cancer (2008) 1.08
Analysis of DNA microarray expression data. Best Pract Res Clin Haematol (2009) 1.03
Unlocking the potential of publicly available microarray data using inSilicoDb and inSilicoMerging R/Bioconductor packages. BMC Bioinformatics (2012) 1.01
Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools. BMC Genomics (2007) 1.01
Green tea catechins suppress the DNA synthesis marker MCM7 in the TRAMP model of prostate cancer. Mol Oncol (2007) 0.97
Comparison of confidence interval methods for an intra-class correlation coefficient (ICC). BMC Med Res Methodol (2014) 0.96
Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration. PLoS One (2008) 0.96
A cross-laboratory comparison of expression profiling data from normal human postmortem brain. Neuroscience (2010) 0.95
Effect of hepatitis C virus core protein on the molecular profiling of human B lymphocytes. Mol Med (2006) 0.90
Biomarker development in the precision medicine era: lung cancer as a case study. Nat Rev Cancer (2016) 0.89
New data on robustness of gene expression signatures in leukemia: comparison of three distinct total RNA preparation procedures. BMC Genomics (2007) 0.89
Identical probes on different high-density oligonucleotide microarrays can produce different measurements of gene expression. BMC Genomics (2006) 0.89
Generalization of DNA microarray dispersion properties: microarray equivalent of t-distribution. Biol Direct (2006) 0.86
Autocorrelation analysis reveals widespread spatial biases in microarray experiments. BMC Genomics (2007) 0.86
Covariance adjustment for batch effect in gene expression data. Stat Med (2014) 0.85
Clinical impact of high-throughput gene expression studies in lung cancer. J Thorac Oncol (2009) 0.84
Genomic markers for decision making: what is preventing us from using markers? Nat Rev Clin Oncol (2009) 0.82
A gene expression profile test to resolve head & neck squamous versus lung squamous cancers. Diagn Pathol (2013) 0.80
Standards affecting the consistency of gene expression arrays in clinical applications. Cancer Epidemiol Biomarkers Prev (2010) 0.80
Kernelized partial least squares for feature reduction and classification of gene microarray data. BMC Syst Biol (2011) 0.80
Distortion of quantitative genomic and expression hybridization by Cot-1 DNA: mitigation of this effect. Nucleic Acids Res (2005) 0.80
Cross-validation and Peeling Strategies for Survival Bump Hunting using Recursive Peeling Methods. Stat Anal Data Min (2016) 0.79
A gene expression profile test for the differential diagnosis of ovarian versus endometrial cancers. Oncotarget (2012) 0.79
Tolerance associated gene expression following allogeneic hematopoietic cell transplantation. PLoS One (2015) 0.79
Estimating relative noise to signal in DNA microarray data. Int J Bioinform Res Appl (2013) 0.78
A sample selection strategy to boost the statistical power of signature detection in cancer expression profile studies. Anticancer Agents Med Chem (2013) 0.77
Microarray experiments and factors which affect their reliability. Biol Direct (2015) 0.77
A network-based method to evaluate quality of reproducibility of differential expression in cancer genomics studies. Oncotarget (2015) 0.75
Genomic-Wide Analysis with Microarrays in Human Oncology. Microarrays (Basel) (2015) 0.75
Comparison of whole blood and peripheral blood mononuclear cell gene expression for evaluation of the perioperative inflammatory response in patients with advanced heart failure. PLoS One (2014) 0.75
William L Gerald, M. D., Ph.D., 1954-2008. J Mol Diagn (2009) 0.75
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med (2002) 21.28
Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci U S A (2002) 20.48
International network of cancer genome projects. Nature (2010) 20.35
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
Endogenous human microRNAs that suppress breast cancer metastasis. Nature (2008) 14.37
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00
PID: the Pathway Interaction Database. Nucleic Acids Res (2008) 12.92
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
A landscape of driver mutations in melanoma. Cell (2012) 12.61
High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat Methods (2008) 12.56
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet (2004) 10.92
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet (2009) 10.54
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
SNPdetector: a software tool for sensitive and accurate SNP detection. PLoS Comput Biol (2005) 10.04
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 9.29
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24
The BioPAX community standard for pathway data sharing. Nat Biotechnol (2010) 9.19
An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res (2004) 8.86
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 8.66
Comprehensive high-throughput arrays for relative methylation (CHARM). Genome Res (2008) 8.62
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Genes that mediate breast cancer metastasis to the brain. Nature (2009) 8.23
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A (2008) 8.08
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Pan-cancer patterns of somatic copy number alteration. Nat Genet (2013) 7.73
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell (2008) 7.60
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst (2007) 7.44
The MGED Ontology: a resource for semantics-based description of microarray experiments. Bioinformatics (2006) 7.37
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
caCORE: a common infrastructure for cancer informatics. Bioinformatics (2003) 7.07
Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature (2009) 7.04
Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med (2006) 6.96
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol (2004) 6.95
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93